Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 8/2021

02.08.2021 | Original Article

Predictive factors for distant recurrence of colorectal cancer in patients after curative resection for stage I–III colorectal cancer in Australia

verfasst von: Swetha Prabhakaran, Joseph C. Kong, Martin Chin, Peter Carne, Chip Farmer, Stewart Skinner, Satish K. Warrier, Stephen Bell

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Distant recurrence is a devastating occurrence after colorectal cancer resection. This study aimed to identify the risk factors for distant recurrence following surgery.

Methods

All consecutive colorectal cancer resections with curative intent were included from a prospectively maintained colorectal cancer database. The primary outcome was to identify predictive factors for distant recurrence of colorectal cancer.

Results

A total of 670 eligible cases were identified with 88 (13.1%) developing distant recurrence during the follow-up period. The median time to distant recurrence was 1.2 years with the most common sites of distant recurrence being the lung (44.3%) and liver (44.3%). Predictive factors for distant recurrence in colon cancer included a high tumor, nodal, and overall stage of the primary cancer (p < 0.001 for all). Surgical complications (p = 0.007), including anastomotic leak (p = 0.023), were associated with a higher risk of developing distant recurrence in rectal cancer patients. Independent variables associated with distant recurrence included tumor stage (OR 1.61, p = 0.011), nodal stage (OR 2.18, p < 0.001), and both KRAS (OR 11.04, p < 0.001) and MLH/PMS2 (OR 0.20, p = 0.035) genetic mutations. Among patients with distant recurrence, treatment with surgery conferred the best survival, with patients < 50 years of age having the best overall 5-year survival.

Conclusion

Predictive factors for distant recurrence include advanced tumor and nodal stages, and the presence of KRAS and MLH/PSM2 mutations. Clinicians should be cognizant of these risk factors, and instate close surveillance plans for patients exhibiting these features.
Literatur
1.
Zurück zum Zitat Bouvier AM, Launoy G, Bouvier V, Rollot F, Manfredi S, Faivre J et al (2015) Incidence and patterns of late recurrences in colon cancer patients. Int J Cancer 137(9):2133–2138CrossRef Bouvier AM, Launoy G, Bouvier V, Rollot F, Manfredi S, Faivre J et al (2015) Incidence and patterns of late recurrences in colon cancer patients. Int J Cancer 137(9):2133–2138CrossRef
2.
Zurück zum Zitat Beck DE, Reickert CA, Margolin DA, Whitlow CB, Timmcke AE, Hicks TC (2006) Local recurrence, distant recurrence and survival of rectal cancer. Ochsner J 6(2):59–63PubMedPubMedCentral Beck DE, Reickert CA, Margolin DA, Whitlow CB, Timmcke AE, Hicks TC (2006) Local recurrence, distant recurrence and survival of rectal cancer. Ochsner J 6(2):59–63PubMedPubMedCentral
3.
Zurück zum Zitat Duineveld LA, van Asselt KM, Bemelman WA, Smits AB, Tanis PJ, van Weert HC et al (2016) Symptomatic and asymptomatic colon cancer recurrence: a multicenter cohort study. Ann Fam Med 14(3):215–220CrossRef Duineveld LA, van Asselt KM, Bemelman WA, Smits AB, Tanis PJ, van Weert HC et al (2016) Symptomatic and asymptomatic colon cancer recurrence: a multicenter cohort study. Ann Fam Med 14(3):215–220CrossRef
4.
Zurück zum Zitat Zafar SN, Hu CY, Snyder RA, Cuddy A, You YN, Lowenstein LM et al (2020) Predicting risk of recurrence after colorectal cancer surgery in the United States: an analysis of a special commission on cancer national study. Ann Surg Oncol 27(8):2740–2749CrossRef Zafar SN, Hu CY, Snyder RA, Cuddy A, You YN, Lowenstein LM et al (2020) Predicting risk of recurrence after colorectal cancer surgery in the United States: an analysis of a special commission on cancer national study. Ann Surg Oncol 27(8):2740–2749CrossRef
5.
Zurück zum Zitat Ho YH, Siu SK, Buttner P, Stevenson A, Lumley J, Stitz R (2010) The effect of obstruction and perforation on colorectal cancer disease-free survival. World J Surg 34(5):1091–1101CrossRef Ho YH, Siu SK, Buttner P, Stevenson A, Lumley J, Stitz R (2010) The effect of obstruction and perforation on colorectal cancer disease-free survival. World J Surg 34(5):1091–1101CrossRef
7.
Zurück zum Zitat Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD et al (2013) Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 31(35):4465–4470CrossRef Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD et al (2013) Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 31(35):4465–4470CrossRef
8.
Zurück zum Zitat Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 23(10):2479–516CrossRef Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 23(10):2479–516CrossRef
9.
Zurück zum Zitat Ryuk JP, Choi GS, Park JS, Kim HJ, Park SY, Yoon GS et al (2014) Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. Ann Surg Treat Res 86(3):143–151CrossRef Ryuk JP, Choi GS, Park JS, Kim HJ, Park SY, Yoon GS et al (2014) Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. Ann Surg Treat Res 86(3):143–151CrossRef
10.
Zurück zum Zitat Cottet V, Bouvier V, Rollot F, Jooste V, Bedenne L, Faivre J et al (2015) Incidence and patterns of late recurrences in rectal cancer patients. Ann Surg Oncol 22(2):520–527CrossRef Cottet V, Bouvier V, Rollot F, Jooste V, Bedenne L, Faivre J et al (2015) Incidence and patterns of late recurrences in rectal cancer patients. Ann Surg Oncol 22(2):520–527CrossRef
11.
Zurück zum Zitat Kong L, Peng J, Li J, Wang F, Li C, Ding P et al (2019) Prolonged surveillance of colorectal cancer patients after curative surgeries beyond five years of follow-up. Ann Transl Med 7(21):608CrossRef Kong L, Peng J, Li J, Wang F, Li C, Ding P et al (2019) Prolonged surveillance of colorectal cancer patients after curative surgeries beyond five years of follow-up. Ann Transl Med 7(21):608CrossRef
12.
Zurück zum Zitat Osterman E, Glimelius B (2018) Recurrence risk after up-to-date colon cancer staging, surgery, and pathology: analysis of the entire Swedish population. Dis Colon Rectum 61(9):1016–1025CrossRef Osterman E, Glimelius B (2018) Recurrence risk after up-to-date colon cancer staging, surgery, and pathology: analysis of the entire Swedish population. Dis Colon Rectum 61(9):1016–1025CrossRef
13.
Zurück zum Zitat Chen TM, Huang YT, Wang GC (2017) Outcome of colon cancer initially presenting as colon perforation and obstruction. World J Surg Oncol 15(1):164CrossRef Chen TM, Huang YT, Wang GC (2017) Outcome of colon cancer initially presenting as colon perforation and obstruction. World J Surg Oncol 15(1):164CrossRef
14.
Zurück zum Zitat Bülow S, Christensen IJ, Iversen LH, Harling H (2011) Intra-operative perforation is an important predictor of local recurrence and impaired survival after abdominoperineal resection for rectal cancer. Colorectal Dis 13(11):1256–1264CrossRef Bülow S, Christensen IJ, Iversen LH, Harling H (2011) Intra-operative perforation is an important predictor of local recurrence and impaired survival after abdominoperineal resection for rectal cancer. Colorectal Dis 13(11):1256–1264CrossRef
15.
Zurück zum Zitat Sugawara K, Kawaguchi Y, Nomura Y, Koike D, Nagai M, Tanaka N (2017) Insufficient lymph node sampling in patients with colorectal cancer perforation is associated with an adverse oncological outcome. World J Surg 41(1):295–305CrossRef Sugawara K, Kawaguchi Y, Nomura Y, Koike D, Nagai M, Tanaka N (2017) Insufficient lymph node sampling in patients with colorectal cancer perforation is associated with an adverse oncological outcome. World J Surg 41(1):295–305CrossRef
16.
Zurück zum Zitat Mayanagi S, Kashiwabara K, Honda M, Oba K, Aoyama T, Kanda M et al (2018) Risk factors for peritoneal recurrence in stage II to III colon cancer. Dis Colon Rectum 61(7):803–808CrossRef Mayanagi S, Kashiwabara K, Honda M, Oba K, Aoyama T, Kanda M et al (2018) Risk factors for peritoneal recurrence in stage II to III colon cancer. Dis Colon Rectum 61(7):803–808CrossRef
17.
Zurück zum Zitat Sugarbaker PH (2014) Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer. World J Gastroenterol 20(28):9286–9291PubMedPubMedCentral Sugarbaker PH (2014) Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer. World J Gastroenterol 20(28):9286–9291PubMedPubMedCentral
18.
Zurück zum Zitat Bell SW, Walker KG, Rickard MJ, Sinclair G, Dent OF, Chapuis PH et al (2003) Anastomotic leakage after curative anterior resection results in a higher prevalence of local recurrence. Br J Surg 90(10):1261–1266CrossRef Bell SW, Walker KG, Rickard MJ, Sinclair G, Dent OF, Chapuis PH et al (2003) Anastomotic leakage after curative anterior resection results in a higher prevalence of local recurrence. Br J Surg 90(10):1261–1266CrossRef
19.
Zurück zum Zitat Walker KG, Bell SW, Rickard MJFX, Mehanna D, Dent OF, Chapuis PH et al (2004) Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. Ann Surg 240(2):255–259CrossRef Walker KG, Bell SW, Rickard MJFX, Mehanna D, Dent OF, Chapuis PH et al (2004) Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. Ann Surg 240(2):255–259CrossRef
20.
Zurück zum Zitat Gestel YV, Herk-Sukel MV, Hingh ID, Rutten H, Creemers G-J, Lemmens VEP (2013) Distant recurrences of colorectal cancer: incidence, systemic treatment, and survival in daily practice. J Clin Oncol 31(4_suppl):441–441 Gestel YV, Herk-Sukel MV, Hingh ID, Rutten H, Creemers G-J, Lemmens VEP (2013) Distant recurrences of colorectal cancer: incidence, systemic treatment, and survival in daily practice. J Clin Oncol 31(4_suppl):441–441
21.
Zurück zum Zitat Sideris M, Moorhead J, Diaz-Cano S, Haji A, Papagrigoriadis S (2017) KRAS mutant status may be associated with distant recurrence in early-stage rectal cancer. Anticancer Res 37(3):1349–1357CrossRef Sideris M, Moorhead J, Diaz-Cano S, Haji A, Papagrigoriadis S (2017) KRAS mutant status may be associated with distant recurrence in early-stage rectal cancer. Anticancer Res 37(3):1349–1357CrossRef
22.
Zurück zum Zitat Sperlich A, Balmert A, Doll D, Bauer S, Franke F, Keller G et al (2018) Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer. BMC Cancer 18(1):998CrossRef Sperlich A, Balmert A, Doll D, Bauer S, Franke F, Keller G et al (2018) Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer. BMC Cancer 18(1):998CrossRef
23.
Zurück zum Zitat Margonis GA, Kim Y, Sasaki K, Samaha M, Amini N, Pawlik TM (2016) Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer 122(17):2698–2707CrossRef Margonis GA, Kim Y, Sasaki K, Samaha M, Amini N, Pawlik TM (2016) Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer 122(17):2698–2707CrossRef
24.
Zurück zum Zitat Knickelbein K, Zhang L (2015) Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis 2(1):4–12CrossRef Knickelbein K, Zhang L (2015) Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis 2(1):4–12CrossRef
25.
Zurück zum Zitat Soulières D, Greer W, Magliocco AM, Huntsman D, Young S, Tsao MS et al (2010) KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol. 17 Suppl 1(Suppl 1):S31–S40CrossRef Soulières D, Greer W, Magliocco AM, Huntsman D, Young S, Tsao MS et al (2010) KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol. 17 Suppl 1(Suppl 1):S31–S40CrossRef
26.
Zurück zum Zitat Takayama Y, Suzuki K, Muto Y, Ichida K, Fukui T, Kakizawa N et al (2018) Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer. Oncotarget 9(36):24398–24413CrossRef Takayama Y, Suzuki K, Muto Y, Ichida K, Fukui T, Kakizawa N et al (2018) Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer. Oncotarget 9(36):24398–24413CrossRef
27.
Zurück zum Zitat Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G et al (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21(7):795–801CrossRef Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G et al (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21(7):795–801CrossRef
28.
Zurück zum Zitat Andre T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt CJA, et al (2020) Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 Study. J Clin Oncol 38(18_suppl):LBA4–LBA Andre T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt CJA, et al (2020) Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 Study. J Clin Oncol 38(18_suppl):LBA4–LBA
29.
Zurück zum Zitat Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520CrossRef Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520CrossRef
30.
Zurück zum Zitat Oliveira AF, Bretes L, Furtado I (2019) Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. Front Oncol 9:396CrossRef Oliveira AF, Bretes L, Furtado I (2019) Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. Front Oncol 9:396CrossRef
31.
Zurück zum Zitat Sutera P, Kalash R, Clump DA, D’Ambrosio D, Mihai A, Burton SA et al (2019) Stereotactic ablative radiation therapy for unresectable colorectal oligometastases. Adv Radiat Oncol 4(1):57–62CrossRef Sutera P, Kalash R, Clump DA, D’Ambrosio D, Mihai A, Burton SA et al (2019) Stereotactic ablative radiation therapy for unresectable colorectal oligometastases. Adv Radiat Oncol 4(1):57–62CrossRef
32.
Zurück zum Zitat Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RLE, Navarria P et al (2014) Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer 14(1):619CrossRef Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RLE, Navarria P et al (2014) Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer 14(1):619CrossRef
Metadaten
Titel
Predictive factors for distant recurrence of colorectal cancer in patients after curative resection for stage I–III colorectal cancer in Australia
verfasst von
Swetha Prabhakaran
Joseph C. Kong
Martin Chin
Peter Carne
Chip Farmer
Stewart Skinner
Satish K. Warrier
Stephen Bell
Publikationsdatum
02.08.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 8/2021
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-021-02273-y

Weitere Artikel der Ausgabe 8/2021

Langenbeck's Archives of Surgery 8/2021 Zur Ausgabe

State-of-the-Art Clinical Surgery

State-of-the-art surgical treatment of IPMNs

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.